Isentress

ORVACS (Objectif Recherche VACcin Sida) has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently bein more

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Mer more

Merck, Sharp & Dohme (MSD) today received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending expanded marketing authorisation for ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infectio more

The human immunodeficiency virus integrase inhibitor, [18F]MK-0518, was prepared via a three-step, one-pot radiosynthesis. [18F]4-Fluorobenzylamine was produced from the fluorination of 4-cyano-N,N,N-trimethylammonium triflate with [18F]fluoride and reduction with borane methylsulfide complex in 50- more

Introduction Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private more

Introduction This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drug more